IMRX — what changed in the latest 10-Q
A section-by-section comparison of IMRX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-10-29 vs the prior 10-Q · 2026-08-05
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +13 | −11 | ~27 | 81 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +4 | −3 | ~9 | 542 |
| Other information | Text added/removed | 0 | 0 | ~1 | 2 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-10-29
•in the first half of 2027, providing additional data from the Phase 2 mGnP Arm;
We expect our general and administrative expenses will increase for the foreseeable future if and as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercializat…
Comparison of the Three Months Ended September 30, 2026 and 2025
General and administrative expenses increased by approximately $0.6 million, or 12.3%, to approximately $5.1 million for the three months ended September 30, 2026, as compared to approximately $4.5 million for the three months ended September 30, 2025. The increase of approximately $0.6 million was …
Comparison of the Nine Months Ended September 30, 2026 and 2025
Text removed vs the prior filing · source: 10-Q · 2026-08-05
available third-party MPACT pivotal trial data for gemcitabine/nab-paclitaxel. Our Phase 1/2a clinical trial of atebimetinib does not include a head-to-head comparison against any other agents, and caution should be exercised when comparing data across trials.
We expect our general and administrative expenses will increase for the foreseeable future if and as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercializat…
also expect to continue to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and rules and regulations of the Securities and Ex…
General and administrative expenses increased by approximately $0.7 million, or 16.3%, to approximately $5.0 million for the three months ended June 30, 2026, as compared to approximately $4.3 million for the three months ended June 30, 2025. The increase of approximately $0.7 million was primarily …
During the six months ended June 30, 2026, operating activities used approximately $34.9 million of cash, primarily resulting from our net loss of approximately $30.7 million, changes in assets and liabilities of $6.9 million, and accretion of discount of marketable securities of $0.9 million. This …
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-10-29
Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that t…
risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and costlier than what is typical for the industry…
•we may be forced to suspend marketing of that product, or be forced to or decide to remove the product from the marketplace;
•the efficacy and safety profile as demonstrated in our clinical trials compared to alternative treatments, which alternative treatments could impact the interpretability of data from such clinical trials (including, without limitation, MAPKeeper 301);
Text removed vs the prior filing · source: 10-Q · 2026-08-05
Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that t…
•we may be forced to suspend marketing of that product, or be forced to or decide to remove the product form the marketplace;
•the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice